XTLB
Xtl BiopharmaceuticalsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About XTLB
Xtl Biopharmaceuticals Ltd.
A biopharmaceutical company that developing drugs for the treatment of autoimmune diseases
Pharmaceutical
03/09/1993
07/15/2013
NASDAQ Stock Exchange
0
12-31
Depository Receipts (Ordinary Shares)
5 Badner St., Ramat Gan, Israel, 5218102
Engaged in the acquisition and research and development of pharmaceutical products.
Xtl Biopharmaceuticals Ltd. was legally established under the laws of the State of Israel on March 9, 1993. The company is engaged in the acquisition and research and development of pharmaceutical products to meet unmet medical needs. Recently working on the treatment of MM, schizophrenia and hepatitis C. The company researches, develops and sells processor-based non-medicinal and non-invasive home therapy devices for the treatment of a variety of diseases. Treated diseases such as high blood pressure, heart failure, insomnia and mental stress.
Company Financials
EPS
XTLB has released its 2022 Q2 earnings. EPS was reported at 0, versus the expected 0, meeting expectations. The chart below visualizes how XTLB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
XTLB has released its 2024 Q4 earnings report, with revenue of 289.00K, reflecting a YoY change of NaN%, and net profit of -255.00K, showing a YoY change of 10.21%. The Sankey diagram below clearly presents XTLB's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
